“Alternative Financing Solutions for Biotechs” Breakfast Seminar: A Thank You to our Attendees & Speakers

by Sheri Farsakh on 7/14/15

Integrium would like to thank everyone who attended "Alternative Financing Solutions for Biotechs: Finance Your Next Clinical Inflection Point." As trusted advisors and clinical proof of concept experts, we hope you have gained a better understanding of the essential necessity for POC Trials when strategizing for safety, efficacy, and capital-raising in your clinical approach.

Complete a Successful Pre-IND Meeting With The FDA

by Sheri Farsakh on 4/22/15

Request a Type B meeting for pre-IND guidance and start building that good rapport with the FDA. Acquire maximum benefit for your strategic plan by engaging the FDA to help facilitate the development process. Although the meeting is not required by the FDA, it is highly recommended and has become more common of a researcher to take this proactive approach prior to undergoing the long and expensive pathway through to regulatory approval.

3 Key Essentials For An Outstanding Biotech Event

by Sheri Farsakh on 4/20/15

In order to create the best environment for a successful biotechnology event to take place, we think 3 key essentials must be met:

The Right Speakers And Topics

Tap into your network of Mavens and construct topics of discussion with specific audience interest in mind

Appropriate Audience

Target your contact list separately by identifying Hot Prospects, Current Customers, and Influencers

Powerful Marketing

Position your event digitally with visual appeal to consider, using all appropriate medium platforms

Regen Med Investor Day – New York

by Sheri Farsakh on 4/1/15

Discussing the invigorating field of regenerative medicine created quite the atmosphere last week when you consider the tremendous potential at hand for investors and patients. Key opinion leaders and life science investment experts and analysts shared their view on the topics at hand:

Gene Therapy Delivery: What can be accomplished with existing vector technology & how should we expect it to evolve?
Adoptive T-Cell Therapies: Considering key upcoming clinical & commercial milestones

The experience took a reviving turn as we spotted some of Integrium's very own clients pitching in front of the various biotech funding groups.

Proof of Concept

by Sheri Farsakh on 3/18/15

Why run a Proof of Concept clinical trial? Well, it's just about the best solution to mitigate risk, minimize cost, and still gain solid safety and efficacy data all before late-stage clinical development. Early drug development challenges raise a lot of risk in which many experts in the industry have realized can be alleviated rather strategically.

Successfully Managing Complicated Trials

February 18th, 2014

Our Medical Affairs team has monitored international outcomes trials with more than 6,000 subjects located at investigator sites around the world. Our trial-tested expertise is why many clients have such confidence in our abilities and why we have provided these services to clients on a stand-alone basis.